Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Trading Down 1.5 %

Cara Therapeutics stock opened at $5.15 on Friday. The firm has a market capitalization of $23.56 million, a P/E ratio of -0.25 and a beta of 0.50. The business has a 50-day moving average of $4.97 and a 200-day moving average of $4.17. Cara Therapeutics has a 1 year low of $2.71 and a 1 year high of $11.52.

Institutional Investors Weigh In On Cara Therapeutics

Several large investors have recently bought and sold shares of the company. FMR LLC boosted its position in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 32,789 shares in the last quarter. XTX Topco Ltd acquired a new stake in Cara Therapeutics during the 3rd quarter worth $29,000. Shay Capital LLC bought a new position in Cara Therapeutics during the fourth quarter worth about $524,000. Rockefeller Capital Management L.P. acquired a new position in Cara Therapeutics in the fourth quarter valued at about $953,000. Finally, Curi RMB Capital LLC bought a new stake in shares of Cara Therapeutics in the fourth quarter worth about $277,000. Institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.